We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Test for Symptomatic Patients Aims to Revolutionize Cancer Diagnosis

By LabMedica International staff writers
Posted on 05 Jun 2023
Print article
Image: Galleri Multi-Cancer Test (Photo courtesy of GRAIL)
Image: Galleri Multi-Cancer Test (Photo courtesy of GRAIL)

Cancer patients generally seek medical attention from a primary care physician only after they begin experiencing related symptoms, such as unexplained weight loss, anemia, or abdominal discomfort. But these symptoms are complex as they can be attributed to various causes. Early detection and intervention of cancer can significantly enhance patient outcomes. Hence, there is a need for innovative tools to speed up cancer diagnosis and potentially eliminate the need for invasive and costly investigations, thus more effectively triaging patients with non-specific cancer symptoms. Now, a novel blood test, capable of detecting over 50 types of cancer, has shown promising results, accurately detecting cancer in two-thirds of more than 5,000 individuals who had consulted their physician due to suspected symptoms. Furthermore, in 85% of these cases, the test accurately identified the original location of the cancer.

The SYMPLIFY study, sponsored by The University of Oxford (Oxford, UK), is the first large-scale evaluation of a multi-cancer early detection (MCED) test from GRAIL, LLC (Menlo Park, CA, USA) among individuals who had consulted their GP due to suspected cancer symptoms. The study enrolled 6,238 participants, aged 18 and above, across England and Wales who were referred for urgent imaging, endoscopy, or other diagnostic methods due to symptoms suggestive of potential gynecological, lung, lower GI or upper GI cancer, or who had presented with non-specific symptoms. All participants provided a blood sample for DNA extraction and testing.

The MCED test from GRAIL detected a cancer signal in 323 individuals, with 244 of these receiving a cancer diagnosis, resulting in a positive predictive value (PPV) of 75.5%, negative predictive value (NPV) of 97.6%, and specificity of 98.4%. The overall sensitivity of the MCED test stood at 66.3%, ranging from 24.2% for stage I cancers to 95.3% for stage IV, and increasing with age and later cancer stage. The overall accuracy of the top CSO prediction following a positive MCED test was 85.2%. The study participants had a mean age of 62.1 years. Encouraged by the study outcomes, GRAIL now aims to broaden its market to include patients demonstrating symptoms linked to cancer, such as unexplained weight loss or abdominal pain.

GRAIL is planning to devise a new test specifically tailored for symptomatic patients, employing the same core technology used in its MCED test. The company hopes to have the new test available in months rather than years. Through a simple blood test, GRAIL aims to minimize reliance on costly scans or invasive biopsies as initial diagnostic procedures for cancer. Medical professionals have expressed enthusiasm about the potential impact of such blood tests in average-risk populations. These tests could serve as a crucial aid in making decisions concerning further diagnostic evaluation for patients. Nevertheless, the efficacy of such blood tests for early cancer detection and their influence on overall patient survival continues to be a topic of debate among clinicians.

“GRAIL’s earlier PATHFINDER study previously demonstrated that adding GRAIL’s MCED testing to standard of care screening more than doubled the number of cancers detected compared with standard screening alone in adults with no symptoms or suspicion of cancer. Now, the SYMPLIFY data confirm the potential benefit of methylation-based MCED blood tests as a diagnostic aid for use in the symptomatic patient population,” said Sir Harpal Kumar, President of GRAIL Europe. “These exciting results will inform our development of an optimized classifier for use in symptomatic patients with a suspicion of cancer.”

Related Links:
GRAIL, LLC

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.